Specific peptide interference reveals BCL6 transcriptional and oncogenic mechanisms in B-cell lympho
Author: ["Jose M Polo","Tania Dell'Oso","Stella Maris Ranuncolo","Leandro Cerchietti","David Beck","Gustavo F Da Silva","Gilbert G Prive","Jonathan D Licht","Ari Melnick"]
Publication: Nature Medicine
CITE.CC academic search helps you expand the influence of your papers.
Abstract
The BTB/POZ transcriptional repressor and candidate oncogene BCL6 is frequently misregulated in B-cell lymphomas. The interface through which the BCL6 BTB domain mediates recruitment of the SMRT, NCoR and BCoR corepressors was recently identified. To determine the contribution of this interface to BCL6 transcriptional and biological properties, we generated a peptide that specifically binds BCL6 and blocks corepressor recruitment in vivo. This inhibitor disrupts BCL6-mediated repression and establishment of silenced chromatin, reactivates natural BCL6 target genes, and abrogates BCL6 biological function in B cells. In BCL6-positive lymphoma cells, peptide blockade caused apoptosis and cell cycle arrest. BTB domain peptide inhibitors may constitute a novel therapeutic agent for B-cell lymphomas.
Cite this article
Polo, J., Dell'Oso, T., Ranuncolo, S. et al. Specific peptide interference reveals BCL6 transcriptional and oncogenic mechanisms in B-cell lymphoma cells. Nat Med 10, 1329–1335 (2004). https://doi.org/10.1038/nm1134
